Ovarian carcinoma of low malignant potential: staging and treatment

Am J Obstet Gynecol. 1986 Feb;154(2):290-3. doi: 10.1016/0002-9378(86)90658-7.

Abstract

A review of 65 cases of ovarian carcinoma of low malignant potential registered at the Manitoba Cancer Treatment and Research Foundation over a 7 1/2-year period was undertaken. Eighty-four percent of patients presented with Stage I disease, which was confirmed by primary staging laparotomy in 25%. The average age at diagnosis was younger than that commonly found in patients with invasive carcinoma. Fourteen patients received postoperative chemotherapy, of whom 10 were evaluated with second-look laparotomy. No patient with macroscopic residual disease after initial surgery was cured by chemotherapy. This report emphasizes the need for a prospective controlled study to evaluate adjunctive chemotherapy in the treatment of these tumors.

MeSH terms

  • Adenocarcinoma, Mucinous / drug therapy
  • Adenocarcinoma, Mucinous / pathology*
  • Adenocarcinoma, Mucinous / surgery
  • Age Factors
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma / drug therapy
  • Carcinoma / pathology*
  • Carcinoma / surgery
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Neoplasm Staging
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / pathology*
  • Ovarian Neoplasms / surgery
  • Ovary / pathology*
  • Retrospective Studies
  • Time Factors